Levosimendan reduces mortality in patients with severe sepsis and septic shock: A meta-analysis of randomized trials

Journal of Critical Care

Volumn 30, Issue 5, 2015, Pages 908-913

  Zangrillo, Alberto ^a,b   Putzu, Alessandro ^a   Monaco, Fabrizio ^a   Oriani, Alessandro ^a   Frau, Giovanna ^a   De Luca, Monica ^a   Di Tomasso, Nora ^a   Bignami, Elena ^a   Lomivorotov, Vladimir ^c   Likhvantsev, Valery ^d   Landoni, Giovanni ^a,b  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c MESHALKIN NATIONAL MEDICAL RESEARCH CENTER   (Russian Federation)

^d M F VLADIMIRSKY MOSCOW REGIONAL RESEARCH CLINICAL INSTITUTE   (Russian Federation)

Author keywords

Anesthesia; Dobutamine; Intensive care; Levosimendan; Septic shock; Severe sepsis

Indexed keywords

DOBUTAMINE; LACTIC ACID; LEVOSIMENDAN; NORADRENALIN; CARDIOTONIC AGENT; HYDRAZONE DERIVATIVE; PYRIDAZINE DERIVATIVE; SIMENDAN;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; DISEASE SEVERITY; FEMALE; FLUID THERAPY; HEART INDEX; HUMAN; LACTATE BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; META ANALYSIS; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEPTIC SHOCK; COMPARATIVE STUDY; MIDDLE AGED; SEPSIS; SHOCK, SEPTIC;

CARDIOTONIC AGENTS; DOBUTAMINE; FEMALE; HUMANS; HYDRAZONES; MALE; MIDDLE AGED; NOREPINEPHRINE; PYRIDAZINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEPSIS; SHOCK, SEPTIC;

EID: 84941316178     PISSN: 08839441     EISSN: 15578615     Source Type: Journal    
DOI: 10.1016/j.jcrc.2015.05.017     Document Type: Article

References (59)

1. Angus D.C., Linde-Zwirble W.T., Lidicker J., Clermont G., Carcillo J., Pinsky M.R. Epidemiology of severe sepsis in the United States: analysis of incidence, outcome, and associated costs of care. Crit Care Med 2001, 29(7):1303-1310.
2. Stevenson E.K., Rubenstein A.R., Radin G.T., Wiener R.S., Walkey A.J. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med 2014, 42(3):625-631.
3. Kaukonen K.M., Bailey M., Suzuki S., Pilcher D., Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA 2014, 311(13):1308-1316.
4. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013, 41(2):580-637.
5. Pro C.I., Yealy D.M., Kellum J.A., Huang D.T., Barnato A.E., Weissfeld L.A., et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med 2014, 370(18):1683-1693.
6. Spies C., Haude V., Fitzner R., Schroder K., Overbeck M., Runkel N., et al. Serum cardiac troponin T as a prognostic marker in early sepsis. Chest 1998, 113(4):1055-1063.
7. Rudiger A., Singer M. Mechanisms of sepsis-induced cardiac dysfunction. Crit Care Med 2007, 35(6):1599-1608.
8. Charpentier J., Luyt C.E., Fulla Y., Vinsonneau C., Cariou A., Grabar S., et al. Brain natriuretic peptide: a marker of myocardial dysfunction and prognosis during severe sepsis. Crit Care Med 2004, 32(3):660-665.
9. Nieminen M.S., Fruhwald S., Heunks L.M., Suominen P.K., Gordon A.C., Kivikko M., et al. Levosimendan: current data, clinical use and future development. Heart Lung Vessel 2013, 5(4):227-245.
10. Sorsa T., Pollesello P., Solaro R.J. The contractile apparatus as a target for drugs against heart failure: interaction of levosimendan, a calcium sensitiser, with cardiac troponin c. Mol Cell Biochem 2004, 266(1-2):87-107.
11. Papp Z., Csapo K., Pollesello P., Haikala H., Edes I. Pharmacological mechanisms contributing to the clinical efficacy of levosimendan. Cardiovasc Drug Rev 2005, 23(1):71-98.
12. Greco T., Calabrò M.G., Covello R.D., Greco M., Pasin L., Morelli A., et al. A Bayesian network meta-analysis on the effect of inodilatatory agents on mortality. Br J Anaesth 2015, 114(5):746-756.
13. Ukkonen H., Saraste M., Akkila J., Knuuti M.J., Lehikoinen P., Nagren K., et al. Myocardial efficiency during calcium sensitization with levosimendan: a noninvasive study with positron emission tomography and echocardiography in healthy volunteers. Clin Pharmacol Ther 1997, 61(5):596-607.
14. Yilmaz M.B., Grossini E., Silva Cardoso J.C., Edes I., Fedele F., Pollesello P., et al. Renal effects of levosimendan: a consensus report. Cardiovasc Drugs Ther 2013, 27(6):581-590.
15. Barraud D., Faivre V., Damy T., Welschbillig S., Gayat E., Heymes C., et al. Levosimendan restores both systolic and diastolic cardiac performance in lipopolysaccharide-treated rabbits: comparison with dobutamine and milrinone. Crit Care Med 2007, 35(5):1376-1382.
16. Garcia-Septien J., Lorente J.A., Delgado M.A., de Paula M., Nin N., Moscoso A., et al. Levosimendan increases portal blood flow and attenuates intestinal intramucosal acidosis in experimental septic shock. Shock 2010, 34(3):275-280.
17. Fries M., Ince C., Rossaint R., Bleilevens C., Bickenbach J., Rex S., et al. Levosimendan but not norepinephrine improves microvascular oxygenation during experimental septic shock. Crit Care Med 2008, 36(6):1886-1891.
18. Zager R.A., Johnson A.C., Lund S., Hanson S.Y., Abrass C.K. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Renal Physiol 2006, 290(6):F1453-F1462.
19. Erbuyun K., Vatansever S., Tok D., Ok G., Turkoz E., Aydede H., et al. Effects of levosimendan and dobutamine on experimental acute lung injury in rats. Acta Histochem 2009, 111(5):404-414.
20. Scheiermann P., Ahluwalia D., Hoegl S., Dolfen A., Revermann M., Zwissler B., et al. Effects of intravenous and inhaled levosimendan in severe rodent sepsis. Intensive Care Med 2009, 35(8):1412-1419.
21. Hasslacher J., Bijuklic K., Bertocchi C., Kountchev J., Bellmann R., Dunzendorfer S., et al. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care 2011, 15(4):R166.
22. Chew M.S., Hawthorne W.J., Bendall J., Whereat S., Huang S., Ting I., et al. No beneficial effects of levosimendan in acute porcine endotoxaemia. Acta Anaesthesiol Scand 2011, 55(7):851-861.
23. Cunha-Goncalves D., Perez-de-Sa V., Grins E., Dahm P.L., Thorne J., Blomquist S. Inotropic support during experimental endotoxemic shock: part I. The effects of levosimendan on splanchnic perfusion. Anesth Analg 2009, 109(5):1568-1575.
24. Cunha-Goncalves D., Perez-de-Sa V., Larsson A., Thorne J., Blomquist S. Inotropic support during experimental endotoxemic shock: part II. A comparison of levosimendan with dobutamine. Anesth Analg 2009, 109(5):1576-1583.
25. Zausig Y.A., Geilfus D., Missler G., Sinner B., Graf B.M., Zink W. Direct cardiac effects of dobutamine, dopamine, epinephrine, and levosimendan in isolated septic rat hearts. Shock 2010, 34(3):269-274.
26. Berry W.T., Hewson R.W., Langrish C.J., McKenzie C.A., Barrett N.A. Levosimendan: a retrospective single-center case series. J Crit Care 2013, 28(6):1075-1078.
27. Powell B.P., De Keulenaer B.L. Levosimendan in septic shock: a case series. Br J Anaesth 2007, 99(3):447-448.
28. Ramaswamykanive H., Bihari D., Solano T.R. Myocardial depression associated with pneumococcal septic shock reversed by levosimendan. Anaesth Intensive Care 2007, 35(3):409-413.
29. Matejovic M., Krouzecky A., Radej J., Novak I. Successful reversal of resistant hypodynamic septic shock with levosimendan. Acta Anaesthesiol Scand 2005, 49(1):127-128.
30. Torraco A., Carrozzo R., Piemonte F., Pastore A., Tozzi G., Verrigni D., et al. Effects of levosimendan on mitochondrial function in patients with septic shock: a randomized trial. Biochimie 2014, 102:166-173.
31. Fang M., Dong S. Effects of levosimendan on hemodynamics and cardiac function in patients with septic shock. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2014, 26(10):692-696.
32. Memis D., Inal M.T., Sut N. The effects of levosimendan vs dobutamine added to dopamine on liver functions assessed with noninvasive liver function monitoring in patients with septic shock. J Crit Care 2012, 27(3):18.e1-18.e6.
33. Morelli A., De Castro S., Teboul J.L., Singer M., Rocco M., Conti G., et al. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med 2005, 31(5):638-644.
34. Morelli A., Donati A., Ertmer C., Rehberg S., Lange M., Orecchioni A., et al. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care 2010, 14(6):R232.
35. Alhashemi J.A., Alotaibi Q.A., Abdullah G.M., Shalabi S.A. Levosimendan vs dobutamine in septic shock. J Crit Care 2009, 24(3):e14-e15.
36. Vaitsis J., Michalopoulou H., Thomopoulos C., Massias S., Stamatis P. Use of levosimendan in myocardial dysfunction due to sepsis. Crit Care 2009, 13(Suppl. 1):165.
37. Landoni G., Biondi-Zoccai G., Greco M., Greco T., Bignami E., Morelli A., et al. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med 2012, 40(2):634-646.
38. Huang X., Lei S., Zhu M.F., Jiang R.L., Huang L.Q., Xia G.L., et al. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials. J Zhejiang Univ Sci B 2013, 14(5):400-415.
39. Higgins J.P.T., Green S. Cochrane handbook for systematic reviews of interventions. Cochrane book series 2008, Cochrane Collaboration, Wiley-Blackwell, Chichester, England; Hoboken, NJ.
40. Moher D., Altman D.G., Liberati A., Tetzlaff J. PRISMA statement. Epidemiology 2011, 22(1):128. [author reply 128].
41. Greco T., Zangrillo A., Biondi-Zoccai G., Landoni G. Meta-analysis: pitfalls and hints. Heart Lung Vessel 2013, 5(4):219-225.
42. Morelli A., Teboul J.L., Maggiore S.M., Vieillard-Baron A., Rocco M., Conti G., et al. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med 2006, 34(9):2287-2293.
43. Michalopoulou H., Stamatis P., Bakhal A., Kelgiorgis T., Foundouli A., Basile A., et al. The calcium sensitizer levosimendan reduces the brain natriuretic peptide levels as compared with dobutamine in intensive care unit septic patients with decompensated heart failure. Crit Care 2007, 11(Suppl. 2):P222.
44. Pinto B.B., Rehberg S., Ertmer C., Westphal M. Role of levosimendan in sepsis and septic shock. Curr Opin Anaesthesiol 2008, 21(2):168-177.
45. Karvouniaris M., Papanikolaou J., Makris D., Zakynthinos E. Sepsis-associated takotsubo cardiomyopathy can be reversed with levosimendan. Am J Emerg Med 2012, 30(5):832.e5-832.e7.
46. Alhashemi J.A. Treatment of cardiogenic shock with levosimendan in combination with beta-adrenergic antagonists. Br J Anaesth 2005, 95(5):648-650.
47. Noto A., Giacomini M., Palandi A., Stabile L., Reali-Forster C., Iapichino G. Levosimendan in septic cardiac failure. Intensive Care Med 2005, 31(1):164-165.
48. Wilkman E., Kaukonen K.M., Pettila V., Kuitunen A., Varpula M. Association between inotrope treatment and 90-day mortality in patients with septic shock. Acta Anaesthesiol Scand 2013, 57(4):431-442.
49. Malik M.M.Y. Levosimendan in myocardial depression due to severe sepsis. Crit Care 2007, 11(Suppl. 2):P226.
50. Morelli A., Rehberg S., Orecchioni A., Cannuovacciuolo N., Bollen Pinto B., Lange M., et al. Effects of levosimendan on renal function in septic shock: a case-control study. Crit Care 2009, 13(Suppl. 1):P170.
51. Morelli A., Ertmer C., Rehberg S., Bollen Pinto B., Orecchioni A., Van Aken H., et al. Effects of levosimendan and inhaled nitric oxide on microcirculation in septic shock. Crit Care 2009, 13(Suppl. 1):P169.
52. de March Ronsoni R., Feijo R.V., Melo L.H., Schwingel F.L., Filho W.J., de Albernaz Muniz R.Z., et al. The use of levosimendan for myocardiopathy due to acute Chagas' disease. Int J Cardiol 2009, 136(2):233-235.
53. Rincón Villegas J.A., Batalla I.M., Córdova Pluma V.H. Tratamiento de la depresión miocárdica por sepsis con levosimendan. Serie de casos y revisión de la bibliografía. Med Int Mex 2010, 26(4):324-336.
54. Adanir T., Yetkin U., Sencan A., Aksun M., Gurbuz A. The role of calcium desensitization in the pathophysiology of septic myocardial depression and effects of levosimendan: results of fifteen septic shock patients. Int J Thorac Cardiovasc Surg 2006, 10(2).
55. Coates J. BET 1: levosimendan in septic shock. Emerg Med J 2014, 31(6):508-510.
56. Oba Y., Lone N.A. Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials. J Crit Care 2014, 29(5):706-710.
57. Walley K.R. Deeper understanding of mechanisms contributing to sepsis-induced myocardial dysfunction. Crit Care 2014, 18(3):137.
58. Cariou A., Pinsky M.R., Monchi M., Laurent I., Vinsonneau C., Chiche J.D., et al. Is myocardial adrenergic responsiveness depressed in human septic shock?. Intensive Care Med 2008, 34(5):917-922.
59. Orme R.M., Perkins G.D., McAuley D.F., Liu K.D., Mason A.J., Morelli A., et al. An efficacy and mechanism evaluation study of Levosimendan for the Prevention of Acute oRgan Dysfunction in Sepsis (LeoPARDS): protocol for a randomized controlled trial. Trials 2014, 15:199.